Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 1.2 years of cash runway.
4 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | — | -$155M | — | — | -$142M | — | $173M |
| 2024 | — | -$178M | — | — | -$166M | — | $114M |
| 2023 | — | -$72M | — | — | -$81M | — | $49M |
| 2022 | — | -$30M | — | — | — | — | $88M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | — | -$39M | — | — | — | — | $113M |
| Dec '25 | — | -$32M | — | — | -$38M | — | $173M |
| Sep '25 | — | -$37M | — | — | -$29M | — | $218M |
| Jun '25 | — | -$43M | — | — | -$30M | — | $102M |
| Mar '25 | — | -$42M | — | — | -$45M | — | $165M |
| Dec '24 | — | -$49M | — | — | -$67M | — | $114M |
| Sep '24 | — | -$56M | — | — | -$50M | — | $97M |
| Jun '24 | — | -$41M | — | — | -$30M | — | $68M |
| Mar '24 | — | -$32M | — | — | -$19M | — | $90M |
| Dec '23 | — | -$24M | — | — | -$29M | — | $49M |
| Sep '23 | — | -$23M | — | — | -$19M | — | $86M |
| Jun '23 | — | -$12M | — | — | -$20M | — | $101M |
| Mar '23 | — | -$13M | — | — | -$13M | — | $138M |
| Dec '22 | — | -$9M | — | — | — | — | $88M |
| Sep '22 | — | -$7M | — | — | — | — | — |
| Jun '22 | — | -$6M | — | — | — | — | — |
| Mar '22 | — | -$8M | — | — | — | — | — |
See the revenue and net-income charts above for Mineralys Therapeutics, Inc.'s multi-year trend.
As of FY2025, Mineralys Therapeutics, Inc. reported — of total debt against $173M of cash.
In FY2025, gross margin was —, operating margin —, and net margin —.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.